BC Extra | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

InDex's UC therapy heading for Phase III  InDex Pharmaceuticals Holding AB (SSE:INDEX) is planning Phase III testing of cobitolimod after the DNA-based immunomodulatory sequence (DIMS) therapy met the primary endpoint in the Phase IIb CONDUCT...
BC Week In Review | Jul 6, 2017
Clinical News

InDex begins Phase IIb of cobitolimod for UC

InDex Pharmaceuticals Holding AB (SSE:INDEX) began the Phase IIb CONDUCT trial of cobitolimod (DIMS 0150) to treat moderate to severe active ulcerative colitis (UC). Top-line data are expected in 4Q18. The double-blind, placebo-controlled, European trial...
BioCentury | Apr 22, 2017

Sweden heating up

Following a nearly 15-year deep freeze, Stockholm has become one of the hottest European markets for biotech IPOs. The recent boom reflects a ripening of several years of investment in the early stage life sciences...
BioCentury | Oct 17, 2016

First North's big fish

As the newest biotech on NASDAQ First North in Stockholm, InDex Pharmaceuticals Holding AB (SSE:INDEX) expects it will receive more attention from investors, as well as have less onerous and costly reporting requirements, compared with...
BC Extra | Oct 11, 2016
Financial News

InDex slides in trading debut

InDex Pharmaceuticals Holding AB (SSE:INDEX) slid SEK1.40 (17%) to SEK7 on Tuesday in its first day of trading after raising SEK250 million ($28.7 million) through the sale of 29.8 million shares at SEK8.40 in an...
BC Week In Review | Jul 20, 2015
Company News

InDex, Almirall deal

The companies terminated a 2014 deal granting Almirall European rights to develop and commercialize Kappaproct . InDex, which now holds worldwide rights to the program, said the termination was due to Almirall’s R&D repositioning, which is...
BioCentury | Oct 20, 2014
Product Development

Walking the toll road

Even after a series of clinical setbacks in the mid-2000s cooled investor and pharma interest in the once white-hot field of toll-like receptors, several companies continued toiling away. Now the spark may be rekindling as...
BC Week In Review | Jun 30, 2014
Clinical News

Kappaproct: Phase III data

Top-line data from the double-blind, European Phase III COLLECT trial in 131 patients with chronic, active, treatment-refractory moderate to severe UC showed that 2 rectal doses of 30 mg Kappaproct given 4 weeks apart as...
BC Extra | Jun 27, 2014
Clinical News

InDex's Kappaproct misses primary endpoint in UC trial

InDex Pharmaceuticals AB (Stockholm, Sweden) said Kappaproct as an add-on to standard therapy missed the primary endpoint of a greater proportion of patients achieving clinical remission at week 12 vs. placebo as an add-on in...
BC Week In Review | Apr 7, 2014
Company News

Almirall, InDex deal

InDex granted Almirall rights to develop and commercialize Kappaproct in Europe. InDex is eligible for up €20 million ($27.5 million) in upfront and "near term" milestone payments and up to €80 million ($110.1 million) in...
Items per page:
1 - 10 of 25